French biopharm company picks Raleigh for its first US manufacturing facility, creating 200 jobs

SourceNews & Observer
Date Published03/07/2019
Author NameZachery Eanes
Mentions specific company case(s) of reshoring, kept from offshoring, or transplantYes

Additional Reshoring Information:

Company/Division name Cellectis
Parent companyCellectis
Type of work Manufacturing
Reshoring category:Foreign Direct Investment
Total number of jobs (added or to be added):200
Year reshoring announced:2019
Year reshoring implemented or to be implemented:2021
Capital investment ($):69
Country(ies) from which reshored:France
City reshored to:Raleigh
State(s) reshored to:NC
If relevant, work nearshored to:-
Product(s) reshoredbiopharm
What domestic positive factors made reshoring more attractive?Eco-system synergies, Government Incentives, Infrastructure, Skilled workforce availability/training
Find Reshoring Articles